Author(s):
Gaurav. N. Patil, Akash. S. Jain, Divakar. R. Patil, Azam. Z. Shaikh, Sameer. R. Shaikh, Hitendra. S. Chaudhari, S. P. Pawar
Email(s):
gp927634@gmail.com
DOI:
10.52711/2349-2988.2026.00040 
Address:
Gaurav. N. Patil1, Akash. S. Jain2, Divakar. R. Patil3, Azam. Z. Shaikh4, Sameer. R. Shaikh5, Hitendra. S. Chaudhari6, S. P. Pawar7
1Student of Final Year B. Pharmacy, P.S.G.V.P. Mandal’s College of Pharmacy, Shahada, India.
2,3,4,5,6Assistant Professors, P.S.G.V.P. Mandal’s College of Pharmacy, Shahada, India.
7Principle P.G.V.P. Mandal’s College of Pharmacy, Shahada, India.
*Corresponding Author
Published In:
Volume - 18,
Issue - 3,
Year - 2026
ABSTRACT:
Digital therapeutics (DTx) mark a major advancement in modern medicine, using advanced software technologies to deliver clinically validated treatments for various physical and mental health conditions. Unlike general wellness apps that focus on fitness or lifestyle tracking, DTx are evidence-based medical interventions developed through rigorous clinical research to ensure safety, efficacy, and measurable outcomes. Delivered via digital platforms such as smartphones, tablets, or specialized medical devices, DTx aim to prevent, manage, and treat diseases through personalized and data-driven care. The rapid progress of information and communication technologies (ICT) has accelerated digital healthcare innovation, as seen with Pear Therapeutics’ reset the first FDA-approved DTx in 2017 for substance use disorder. This milestone signaled the start of a new era in medicine, where digital treatments can complement or even replace traditional drug-based therapies. Chronic diseases like diabetes, cardiovascular disorders, and respiratory illnesses cause over 70% of global deaths, often due to poor lifestyle habits and aging populations. DTx offer continuous, personalized care through real-time monitoring, behavioral insights, and feedback, helping patients manage their conditions more effectively. Technologies such as augmented reality (AR) and virtual reality (VR) further enhance outcomes by improving adherence, reducing medical errors, and lowering hospitalization rates. Since the FDA’s first approval, the DTx market has expanded rapidly, with over 400 products now available or in development to address conditions from depression and insomnia to diabetes and hypertension. Their key advantages accessibility, affordability, and scalability make DTx a powerful alternative to traditional, in-person healthcare. By merging clinical science with digital innovation, digital therapeutics are reshaping the healthcare landscape, shifting it from reactive illness treatment toward proactive, preventive, and personalized care for long-term well-being.
Cite this article:
Gaurav. N. Patil, Akash. S. Jain, Divakar. R. Patil, Azam. Z. Shaikh, Sameer. R. Shaikh, Hitendra. S. Chaudhari, S. P. Pawar. Digital Therapeutics for Management of Chronic Diseases. Research Journal of Science and Technology. 2026; 18(3):284-2. doi: 10.52711/2349-2988.2026.00040
Cite(Electronic):
Gaurav. N. Patil, Akash. S. Jain, Divakar. R. Patil, Azam. Z. Shaikh, Sameer. R. Shaikh, Hitendra. S. Chaudhari, S. P. Pawar. Digital Therapeutics for Management of Chronic Diseases. Research Journal of Science and Technology. 2026; 18(3):284-2. doi: 10.52711/2349-2988.2026.00040 Available on: https://www.rjstonline.com/AbstractView.aspx?PID=2026-18-3-7
REFERENCES:
1. Chung JY. Digital therapeutics and clinical pharmacology. Clin Pharmacol Ther. 2019;27(1):6–11.
2. Ju JH, Sim B, Lee JY, Lee J. Reimbursement of digital therapeutics: Future perspectives in Korea. Korean Circ J. 2022;52(4):265–279.
3. Shah AM, Shah SV. Digital therapeutics—A new era in healthcare. Natl J Physiol Pharm Pharmacol. 2023;13(11).
4. James OO, Olawale M. Advancing chronic disease management: Role of digital health technologies. Appl Sci Comput Energy. 2022;2(2):220–243.
5. Ikram M, Shah I, Pirzada AS, et al. Designing and evaluating digital therapeutic interventions using VR and AR. JHWCR.
6. Sapanel Y, Tadeo X, Brenna CTA, et al. Economic evaluation of mobile-based digital therapeutics: Systematic review.
7. John B, Johnson B, Liang W, et al. Digital therapeutics: How technology is changing treatment for chronic diseases. 2025.
8. Saeed H, Malik H, Bashir U, et al. Blockchain technology in healthcare: A systematic review.
9. Strudwick G. Predicting nurses’ use of healthcare technology using TAM: An integrative review.
10. Herndon JH, Hwang R, Bozic KH. Healthcare technology and technology assessment.
11. Al Kuwaiti A, Nazer K, Al-Reedy A, et al. Role of artificial intelligence in healthcare.
12. Tilala MH, Chenchala PK, Choppadandi A, et al. Ethical considerations of AI and ML in healthcare.
13. Mirza M, Jabeen H, Fatima A. Artificial intelligence in digital therapeutics for optimized healthcare.
14. Udegbe FC, Ebulue OR, Ebulue CC, Ekesiobi CS. Role of AI in healthcare: A systematic review.
15. Dias D, Cunha JPS. Wearable health devices and vital sign monitoring. Sensors. 2018;18.
16. Jafleh EA, Alnaqbi FA, Almaeeni HA, et al. Role of wearable devices in chronic disease monitoring.
17. Ramakrishnan P, Yan K, Balijepalli C, Druyts E. Digital therapeutics in diabetes management.
18. American Diabetes Association. Standards of medical care in diabetes. Clin Diabetes. 2020;38(1):10.
19. Jacksonville University School of Nursing. Digital technologies for diabetes distress.
20. Ejel BAL, Sattar S, Fatima SB, et al. Digital diabetes management technologies: Systematic review.
21. Kario K, Harada N, Okura A. Digital therapeutics in hypertension. Hypertension. 2022;79(10):2148–2158.
22. Kario K, Nomura A, Harada N, et al. HERB-DH1 trial design. J Clin Hypertens. 2020; 22:1713–1722.
23. Katsuya T, Hisaki F, Aga M, et al. CureApp HT and physician-patient communication.
24. Gonzales S, Okusaga OO, Reuteman-Fowler JC, et al. Digital medicine system in mental illness. JMIR Form Res. 2022;6: e34893.
25. Rehman A, Jamil T, Baloch SK, et al. Digital therapeutics in mental health care.
26. Khokhar S, Holden J, Toomer CH, et al. AI-based digital therapeutics for obesity.
27. Lee H, Youm S. Digital therapeutics for obesity using 3D body reconstruction.
28. Kang SG, Kang JM, Cho SJ, et al. CBT mobile app for insomnia. J Clin Sleep Med. 2017;13(4).
29. Khirasaria R, Singh V, Batta A. Exploring digital therapeutics in healthcare.
30. Camacho M, Robertson M, Abdullatif J, et al. Smartphone apps for snoring. J Laryngol Otol. 2015.
31. Sullivan AN, Lachman ME. Behavior change with fitness technology. Front Public Health. 2017; 4:289.
32. Linares-del Rey M, Vela-Desojo L, Cano-de la Cuerda R. Apps in Parkinson’s disease. Neurologia. 2019;34(1):38–54.
33. Katwa U, Rivera E. Asthma management with smart devices. Indian J Pediatr. 2018; 85:757–762.
34. Ologundudu L, Rayner DG, Oppenheimer J, et al. Digital inhalers for asthma: Systematic review.
35. Chrystyn H, Saralaya D, Shenoy A, et al. Accuracy of Digihaler. J Aerosol Med Pulm Drug Deliv. 2022; 35:166–177.
36. Abidi SR, Rickards T, Abidi SSR. Digital therapeutics for COPD self-management. MEDINFO. 2023.
37. Chan AHY, Pleasants RA, Dhand R, et al. Digital inhalers for COPD. Pulm Ther. 2021; 7:345–376.
38. Seheult JN, O’Connell P, Tee KC, et al. Aerosol delivery in inhalers. Pharm Res. 2014;31(10):2735–2747.
39. McCarthy M, Schueler P. Digital tech in Alzheimer’s treatment. J Prev Alzheimers Dis. 2019;6(4):217–220.
40. Zhang Y, Zhang Y, Jiang Z, et al. EEG and fNIRS in Alzheimer’s therapy. Front Neurosci. 2023; 17:1269359.
41. Elfaki AO, Alotaibi M. mHealth apps in Alzheimer’s care. mHealth. 2018; 4:32.
42. Wang C, Lee C, Shin H. Digital therapeutics from bench to bedside. NPJ Digit Med. 2023; 6:38.
43. Romagnoli A, Valentino F, Zovi A, et al. Development of digital therapies. J Pharm Innov. 2023.
44. NICE. Evidence standards framework for digital health technologies. 2021.
45. Yan K, Balijepalli C, Druyts E. Impact of digital therapeutics on HTA. Front Digit Health. 2021; 3:667016.
46. Fürstenau D, Gersch M, Schreiter S. Digital therapeutics. Bus Inf Syst Eng. 2023; 65:349–360.
47. Sverdlov O, van Dam J, Hannesdottir K, Thornton-Wells T. Digital therapeutics in drug development. Clin Pharmacol Ther. 2018; 104:72–80.
48. Colloud S, Metcalfe T, Askin S, et al. Regulatory perspectives on digital health. NPJ Digit Med. 2023; 6:56.
49. Rassi-Cruz M, Valente F, Caniza MV. Need for regulation in digital therapeutics. Diabetol Metab Syndr. 2022; 14:48.
50. Crisafulli S, Santoro E, Recchia G, Trifirò G. Digital therapeutics regulation and challenges.
51. Adams T, Connor M, Whittaker R. Protecting digital medicine infrastructure. NPJ Digit Med. 2019; 2:97.
52. Golbus JR, Price WN, Nallamothu BK. Privacy gaps in digital health data. Circulation. 2020;141(8):613–615.
53. Lehne M, Sass J, Essenwanger A, et al. Importance of interoperability. NPJ Digit Med. 2019; 2:79.
54. Zhang H, Cao Y, Jiang H, et al. Future of digital health. Clin Transl Allergy. 2025; e70020.
55. Digital therapeutics: Challenges and opportunities.
56. Whitehead L, Talevski J, Fatehi F, Beauchamp A. Barriers in digital health adoption. J Med Internet Res. 2023;25:e42719.
57. Stoumpos AI, Kitsios F, Talias MA. Digital transformation in healthcare. Int J Environ Res Public Health. 2023; 20:3407.
58. Watson A, Chapman R, Shafai G, Maricich YA. FDA regulations and DTx. Front Digit Health. 2023; 5:1086219.
59. Huh KY, Oh J, Lee SH, Yu KS. Clinical evaluation of digital therapeutics. Healthc Inform Res. 2022;28(3):188–197.
60. Ramani VK, Suresh KP. Prevalence of hypertension and diabetes. J Family Med Prim Care. 2020; 9:3264–3271.